<DOC>
	<DOCNO>NCT00404781</DOCNO>
	<brief_summary>Effects dual antiplatelet therapy aspirin clopidogrel percutaneous coronary intervention proven . However , patient low response agent report associated adverse clinical outcome . We suppose optimized antiplatelet therapy individual patient base platelet function assay may improve long-term outcome especially patient high risk thrombosis . In prospective randomized study , patient control group receive standard dual antiplatelet therapy , patient optimize group receive different antiplatelet therapy accord risk stratification .</brief_summary>
	<brief_title>Effects Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>nonSTsegment elevate acute coronary syndrome patient undergo selective emergent PCI administration clopidogrel ticlopidine within 2 week STsegment elevate myocardial infarction contraindication antiplatelet therapy history intracranial bleeding know bleed disorder severe liver kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>ischemic heart disease</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>percutaneous transluminal coronary angioplasty</keyword>
	<keyword>platelet function</keyword>
	<keyword>aspirin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>cilostazol</keyword>
</DOC>